My final earnings short-squeeze candidate is biotechnology and drugs player Pacira Pharmaceuticals (PCRX), which just released numbers on Tuesday morning. This is a pharmaceutical company engaged in the development, commercialization, and manufacture of pharmaceutical products for hospitals and ambulatory surgery centers.
Pacira Pharma missed Wall Street estimates for the fourth quarter after reporting a loss of 72 cents vs. the consensus for a loss of 54 cents. Revenue was slightly better than Wall Street estimates at $4.23 million vs. the consensus of $4.05 million. The company also said that it expects to initiate the commercial launch of Exparel in the U.S. during the week of April 9. Exparel was approved by the FDA in October 2011.The current short interest as a percentage of the float for Pacira Pharmaceuticals is pretty high at 12.6%. That means that out of the 12.08 million shares in the tradable float, 1.83 million are sold short by the bears. The bears have also been increasing their bets from the last reporting period by 2.7%, or by about 48,000 shares. From a technical perspective, PCRX is currently trading above both its 50-day and 200-day moving averages, which is bullish. This stock has found some decent buying interest over the last two months at around $10 a share. The stock has also been making higher highs and higher lows over those two months, which is bullish price action. Now PCRX is trading within range of a big breakout trade post-earnings. If you're bullish on PCRX, I would look for long-biased trades after its report if it can manage to break out above $12.01 to $12.10 a share with high-volume. Look for volume that registers close to or above its three-month average volume of 126,650 shares. If we get that action, I would then add to any long positions once PCRX takes out $13 a share with volume. A move over $13 will give PCRX a great chance to re-test its all-time high of $15.34 in the near future. I would simply avoid PCRX or look for short-biased trades after its report if the stock fails to break out and then drops below $10, and its 200-day moving average of $9.68 a share with high-volume. Target a drop back towards $8.50 a share or lower if the bears hammer this down post-earnings. To see more potential earnings short squeeze plays, including Sealy (ZZ), Family Dollar Stores (FDO) and Charming Shoppes (CHRS), check out the Earnings Short Squeeze Plays portfolio on Stockpickr. -- Written by Roberto Pedone in Winderemere, Fla.
Twitter and become a fan on Facebook.
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass + 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV